5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026Zacks Investment Research • 12/16/25
Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity ConferenceGlobeNewsWire • 11/20/25
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial ResultsGlobeNewsWire • 10/23/25
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in KoreaGlobeNewsWire • 09/15/25
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025GlobeNewsWire • 09/02/25
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt DiseaseGlobeNewsWire • 08/13/25
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and WarrantsGlobeNewsWire • 08/12/25
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and WarrantsGlobeNewsWire • 08/08/25
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership TeamGlobeNewsWire • 07/21/25
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt DiseaseGlobeNewsWire • 07/18/25
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial ResultsGlobeNewsWire • 07/17/25
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic DiseasesGlobeNewsWire • 06/23/25